There is currently no officially established recommended daily allowance for sulforaphane. Human studies have commonly evaluated approximately 25-200 umol of sulforaphane per day, equivalent to about 4.4-35.5 mg of direct sulforaphane. However, doses cannot be compared without identifying whether a product contains direct sulforaphane, glucoraphanin with myrosinase, or glucoraphanin alone.
Table of Contents
- Introduction: How Much Sulforaphane Should You Take Per Day?
- Is There an Official Recommended Daily Dose for Sulforaphane?
- First Identify Which “Sulforaphane” Form You Are Taking
- How to Convert Sulforaphane Between Milligrams and Micromoles
- What Dosages Have Been Used in Human Studies?
- A Research-Informed Interpretation of Daily Dosage
- How Much Glucoraphanin With Myrosinase Per Day?
- Once Daily or Split Doses?
- Should Sulforaphane Be Taken With Food?
- Sulforaphane Dosage and Possible Side Effects
- Who Should Seek Medical Advice Before Using Sulforaphane?
- Dosage-Formulation Recommendations for Supplement Brands
- What Brands Must Test Before Setting the Serving Size
- Regulatory Considerations for Dosage Claims
- Frequently Asked Questions
- Conclusion
When consumers search for “sulforaphane dosage” or “how much sulforaphane per day,” they often expect a simple milligram recommendation. The reality is more nuanced. Clinical trial doses do not equal recommended doses. Different studies use different populations, formulations, durations, and endpoints. Direct sulforaphane (SFN) and glucoraphanin (GR) cannot be compared using the same milligram values. The conversion of GR to SFN depends heavily on myrosinase activity. And the total weight of a “broccoli extract” listed on a product label does not represent the actual bioactive dose.
This guide explains what the research actually shows, how to interpret different dosage forms, and what supplement brands should consider when setting a serving size.
Brands developing a standardized formula can explore our Sulforaphane Supplement Manufacturing Services
Is There an Official Recommended Daily Dose for Sulforaphane?
The direct answer is: no. Sulforaphane currently has no Recommended Dietary Allowance (RDA), no FDA Daily Value, no official Upper Limit, and no universal recommendation that applies to all populations. Supplement Facts panels for sulforaphane products typically state “Daily Value not established.”
The U.S. Food and Drug Administration (FDA) regulates dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which does not require pre-market approval for supplement ingredients unless they are new dietary ingredients. Under current FDA guidance, manufacturers are responsible for ensuring their products are safe and that any claims are truthful and not misleading.
- No RDA established for sulforaphane
- No FDA Daily Value assigned
- No official Upper Limit defined
- No unified recommendation for all populations
- Supplement Facts should state “Daily Value not established”
When communicating about sulforaphane dosage, brands should avoid phrases such as “FDA-recommended dose,” “clinically approved daily dose,” “proven optimal dosage,” or “safe at any dose.” These are not only inaccurate but may also create regulatory risk.
First Identify Which “Sulforaphane” Form You Are Taking
Before comparing any dosage numbers, it is essential to identify which form of sulforaphane-related ingredient a product actually contains. The term “sulforaphane” is often used loosely in marketing, but the bioactive delivery pathway differs significantly across four main categories.
Direct or Stabilized Sulforaphane
Products in this category list direct sulforaphane on the label, often as “sulforaphane,” “stabilized sulforaphane,” or “active sulforaphane.” This form does not require conversion from glucoraphanin and is already in the bioactive isothiocyanate form.
Advantages include predictable dosing (easier to compare in both mg and umol), potentially lower individual variability, and faster availability in circulation. However, challenges include sensitivity to heat, moisture, and oxidation; the need to verify actual content throughout shelf life; gastrointestinal tolerability at higher doses; and the requirement for finished-product quantitative testing using validated analytical methods.
Glucoraphanin with Active Myrosinase
This formulation provides glucoraphanin (typically from broccoli seed extract) combined with a source of active myrosinase enzyme (from broccoli sprout, mustard seed, or other sources). The myrosinase catalyzes the conversion of GR to SFN after ingestion, usually in the gastrointestinal tract.
A 2026 randomized crossover human study found that when 50 mg of glucoraphanin was combined with mustard seed myrosinase of defined activity, mean sulforaphane bioavailability increased from 18.6% to 39.8% compared to GR without added myrosinase. This demonstrates that co-delivery of GR and active myrosinase can substantially improve SFN yield.
Sources:
Important: 50 mg glucoraphanin does not mean the consumer receives 50 mg sulforaphane.
Glucoraphanin Without Active Myrosinase
Some products contain glucoraphanin alone, without an added myrosinase source. In this case, conversion to sulforaphane depends entirely on endogenous factors: gut microbiota with myrosinase-like activity, individual microbial composition, digestive pH, and transit time.
This pathway is associated with lower and more variable conversion rates, significant inter-individual differences in SFN production, potentially delayed onset of metabolite appearance, and unreliable dose-to-response relationships. Products in this category should not market theoretical 100% conversion yields as actual delivered doses.
Broccoli Sprout Powder or Whole Sprouts
Whole food sources such as broccoli sprout powder or fresh sprouts present the greatest variability in actual sulforaphane content. Precise dosing is difficult because content depends on multiple factors:
- Seed variety and glucoraphanin potential
- Number of germination days
- Temperature during growth
- Processing and drying methods
- Endogenous myrosinase activity
- Epithiospecifier protein (ESP) activity
- Storage conditions and duration
- Degree of chewing or mechanical disruption
How to Convert Sulforaphane Between Milligrams and Micromoles
Scientific studies typically report sulforaphane and glucoraphanin doses in micromoles (umol), while supplement labels usually list milligrams (mg). Understanding the conversion is essential for comparing products and interpreting research.
Sulforaphane Conversion
The molecular weight of sulforaphane is approximately 177.29 g/mol. The conversion formula is:
SFN (umol) = SFN (mg) / 0.17729
Common conversions:
| SFN (mg) | SFN (umol) |
| 5 mg | ~28 umol |
| 10 mg | ~56 umol |
| 20 mg | ~113 umol |
| 25 mg | ~141 umol |
| 30 mg | ~169 umol |
| 60 mg | ~338 umol |
Glucoraphanin Conversion
The molecular weight of glucoraphanin is approximately 436.5 g/mol. The conversion formula is:
GR (umol) = GR (mg) / 0.4365
Common conversions:
| GR (mg) | GR (umol) |
| 25 mg | ~57 umol |
| 30 mg | ~69 umol |
| 35 mg | ~80 umol |
| 50 mg | ~115 umol |
| 100 mg | ~229 umol |
Why the Theoretical Yield Can Be Misleading
Glucoraphanin and sulforaphane convert theoretically on a 1:1 molar basis. For example, 35 mg GR is approximately 80 umol, which could theoretically yield up to about 14.2 mg of SFN at 100% conversion. However, actual yields are typically well below this theoretical maximum.
Actual SFN production depends on myrosinase activity (source, units, stability), pH conditions at the conversion site, the location of release (stomach vs. small intestine), and individual differences in digestive physiology and microbiota. Brands should not state that a product “delivers 14.2 mg sulforaphane” from 35 mg GR unless finished-product testing or human pharmacokinetic data supports that claim.
What Dosages Have Been Used in Human Studies?
Note: The following section is titled “Human Study Doses,” not “Recommended Doses.” These are research protocols, not consumer recommendations.
25-150 umol Per Day
A randomized trial in COPD patients studied 25 umol SFN per day (approximately 4.4 mg) and 150 umol SFN per day (approximately 26.6 mg) over a 4-week period. The study did not demonstrate improvement in all targeted biomarkers, which means these doses should not be marketed as proven effective treatment doses for any condition.
50-200 umol Per Day
A 28-day study administered sulforaphane at three dose levels: 50 umol per day (approximately 8.9 mg), 100 umol per day (approximately 17.7 mg), and 200 umol per day (approximately 35.5 mg). All 17 subjects completed the study without dose-limiting toxicity, though the sample size was small and the population was specific.
40 umol SFN Plus 600 umol GR
A 12-week study with 291 participants used a broccoli sprout beverage providing 40 umol of preformed SFN (approximately 7.1 mg) plus 600 umol of glucoraphanin (approximately 262 mg) daily. This was a specific research beverage formulation and the total GR dose should not be directly translated into general capsule supplement recommendations.
Approximately 95 umol Per Day for 12 Months
A 2025 randomized trial in former smokers used a potential daily dose of approximately 95 umol SFN for 12 months. Results showed changes in certain tissue biomarkers but not in all primary histological endpoints. No serious adverse events were observed. However, this does not justify marketing sulforaphane for lung cancer prevention or treatment.
60 mg Stabilized SFN Per Day
A prostate-related clinical study used 60 mg of stabilized free sulforaphane per day (approximately 338 umol) for 6 months in men at risk of prostate cancer. The primary endpoint was not met. This was a disease-population study and cannot serve as a daily recommendation for general consumers. It also does not support marketing claims about prostate cancer treatment or prevention.
260-520 umol in a Short Phase I Study
A 2024 Phase I study of SFX-01 (an alpha-cyclodextrin-stabilized sulforaphane formulation) tested 46.2 mg SFN (approximately 260 umol) and 92.4 mg SFN (approximately 520 umol) for 7 days in healthy male volunteers. While no serious dose-limiting issues were observed, 94% of active treatment subjects reported adverse events during the treatment period, primarily mild gastrointestinal symptoms.
A high dose being tolerated for seven days in a controlled Phase I study does not establish a safe long-term retail supplement dose.
A Research-Informed Interpretation of Daily Dosage
The following framework organizes the human study data into three tiers. These are descriptive ranges based on published research, not official recommendations.
Lower Commercial Range
Approximately 5-10 mg of direct sulforaphane, or 28-56 umol. This range may be suitable for entry-level products, single-capsule low-dose positioning, markets where gastrointestinal tolerability is a priority, and formulations designed for flexible daily adjustment. This is a commercial formulation range, not an official health recommendation.
Common Human-Study Range
Approximately 25-200 umol of direct or equivalent sulforaphane, or 4.4-35.5 mg. This range appears in multiple human studies. The specific effects and tolerability within this range depend on formulation type, study population, duration of use, actual bioavailability, presence of myrosinase, and whether the dose is taken with food.
Higher Clinical-Research Range
Above 200 umol, or approximately 35 mg of direct sulforaphane. Doses in this range are typically used in specific disease-targeted or drug-development research and are not appropriate for general retail supplement recommendations. Higher doses may increase the likelihood of nausea, abdominal discomfort, vomiting, and diarrhea, and should only be used under professional supervision.
A review article noted that a broccoli sprout beverage providing approximately 450 umol may exceed the tolerable level for many healthy subjects, while 200 umol or lower may represent a more acceptable upper range for that beverage type. This observation should not be generalized to all dosage forms.
How Much Glucoraphanin With Myrosinase Per Day?
Direct SFN doses cannot be simply reverse-calculated into GR input amounts. The following example illustrates why:
- 50 mg GR equals approximately 115 umol
- Combined with approximately 50 units of mustard seed myrosinase
- Human mean bioavailability/ conversion: approximately 39.8%
- Individual range remains wide
- The same 50 mg GR without exogenous myrosinase: mean approximately 18.6%
For transparency, brands should consider labeling the following:
- GR content in mg
- GR content in umol
- Myrosinase source
- Myrosinase activity in defined units
- In vitro SFN generation yield
- Testing pH and reaction conditions
Avoid vague labels such as “500 mg Sulforaphane Complex” that do not specify actual glucoraphanin or sulforaphane content.
Once Daily or Split Doses?
Current research does not prove that one dosing schedule is universally superior for all products. What is known:
- Non-enteric-coated SFN typically reaches peak plasma levels within approximately 1-3 hours
- Enteric-coated formulations may delay absorption to 3-6 hours
- Most metabolites are substantially cleared within 24 hours
- Split dosing may improve gastrointestinal tolerability for some consumers
- Whether split dosing improves long-term efficacy has not been established
Sources:
Brands should determine dosing instructions based on their specific product’s disintegration data, release location, human tolerability data, per-capsule dose, and target use case rather than copying another brand’s directions.
Should Sulforaphane Be Taken With Food?
The answer depends on the formulation. Some studies have administered sulforaphane on an empty stomach or away from large meals. Other high-concentration products have been taken with food to reduce nausea. Food may affect different formulation types differently.
Brands should avoid blanket claims such as “absorption is better on an empty stomach” without formulation-specific data. For OEM brands, it is advisable to conduct fasting versus fed tolerability testing, post-dose gastrointestinal response surveys, and if needed, design split-dose protocols rather than making unstudied absorption claims.
Sulforaphane Dosage and Possible Side Effects
Commonly reported adverse effects in human studies include:
- Abdominal discomfort
- Nausea
- Gas and bloating
- Diarrhea
- Constipation
- Sulfur-like taste or odor
- Vomiting (less common)
- Headache (reported in individual studies)
Higher doses do not necessarily produce stronger beneficial effects. A 2023 systematic review of randomized trials noted that study doses varied widely, results were inconsistent, and no unified optimal dose has been established.
Who Should Seek Medical Advice Before Using Sulforaphane?
The following groups should consult a qualified healthcare professional before using sulforaphane supplements:
- Pregnant or breastfeeding individuals
- Children
- People receiving cancer treatment
- People taking prescription medications
- Individuals with significant gastrointestinal sensitivity
- People with thyroid disorders or restricted iodine intake
- Anyone preparing for surgery
- Anyone considering a high-dose research-style protocol
The Linus Pauling Institute notes that safety data for high-dose purified isothiocyanate supplements during pregnancy and lactation are lacking.
Parents should not use clinical study doses in children for self-medication, and no autism treatment claims should be made.
Dosage-Formulation Recommendations for Supplement Brands
The following are product development concepts for brands, not medical dosage recommendations for consumers.
Concept A — Lower-Dose Direct SFN Capsule
Development target: 5-10 mg stabilized sulforaphane per serving, with 1-2 capsule flexible serving size, low water activity excipients, high-barrier packaging, and finished-product quantification throughout shelf life. Suitable for premium wellness positioning, direct-active ingredient marketing, and gastrointestinal tolerability-priority markets.
Concept B — Standardized GR + Active Myrosinase
Development target: 30-50 mg glucoraphanin per serving with defined-activity mustard seed or broccoli myrosinase, dual-labeling in mg and umol, delayed-release capsule technology, and end-of-shelf-life enzyme activity and SFN generation rate validation. Suitable for research-aligned positioning, ambient temperature stability requirements, and mid-to-premium market segments.
Concept C — Flexible Split-Serving Formula
Design: low per-capsule dose with a 2-capsule per-serving design, allowing consumers to split doses according to label directions. This avoids single-dose high concentration release and includes gastrointestinal tolerability guidance on the label.
These are product development benchmarks, not medical dosage recommendations for all consumers.
What Brands Must Test Before Setting the Serving Size
Raw Material Testing
- Sulforaphane or glucoraphanin identity verification
- Actual SFN or GR content by validated assay
- Myrosinase activity in defined units
- Moisture content
- Water activity
- Contaminant screening (heavy metals, microbes)
- Botanical identity confirmation
Finished Product Testing
- Per-serving SFN or GR content
- Actual SFN yield after GR conversion
- Disintegration and dissolution/release profile
- Content uniformity across batch
- Accelerated stability data
- Real-time stability data
- End-of-shelf-life myrosinase activity
- SFN generation rate at different pH conditions
Consumer Tolerance Assessment
- Single-capsule vs. full-serving tolerability
- Fasting vs. fed administration response
- Incidence of stomach discomfort
- Odor and aftertaste evaluation
- Capsule count and swallowing experience
Regulatory Considerations for Dosage Claims
Acceptable label statements:
- “Provides 10 mg of stabilized sulforaphane per serving”
- “Provides 35 mg of glucoraphanin with active myrosinase”
- “Take two capsules daily”
- “Daily Value not established”
Claims to avoid:
- “The medically recommended dose”
- “Guaranteed therapeutic dose”
- “Prevents cancer at 20 mg per day”
- “Treats autism at 2.2 umol/kg”
- “Higher doses provide stronger detoxification”
- “Equivalent to a clinical treatment”
For structure/function claim guidance, refer to FDA regulations. For advertising substantiation, consult FTC guidance on health product claims.
- FDA: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-F/section-101.93
- FTC: https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
Frequently Asked Questions
Q: How much sulforaphane should an adult take daily?
A: There is no officially established daily dose. Human studies have commonly evaluated approximately 25-200 umol, or 4.4-35.5 mg of direct sulforaphane per day, but these are research doses rather than universal recommendations.
Q: Is 10 mg of sulforaphane a high dose?
A: Ten milligrams equals approximately 56 umol. It falls within doses evaluated in some human studies, but tolerability and delivery depend on the formulation.
Q: Is 35 mg glucoraphanin equal to 35 mg sulforaphane?
A: No. Thirty-five milligrams of GR is about 80 umol and has a theoretical maximum yield of approximately 14.2 mg SFN. Actual conversion is lower and variable.
Q: How much glucoraphanin should a supplement contain?
A: There is no official daily recommendation. The formula should be evaluated together with myrosinase activity and verified SFN yield.
Q: Can I take sulforaphane twice a day?
A: Some clinical formulations have used divided doses, but there is no evidence that twice-daily use is universally superior. Follow the specific product directions.
Q: Can sulforaphane be taken long term?
A: Some studies have lasted several months or up to one year, but long-term evidence remains formulation- and population-specific.
Q: Can children take sulforaphane?
A: Children should not receive research-style sulforaphane doses without guidance from a qualified healthcare professional.
Q: Does a higher dose work better?
A: Not necessarily. Higher intake may increase gastrointestinal side effects, while clinical dose-response results remain inconsistent.
Conclusion
There is no universal answer to how much sulforaphane a person should take per day. A meaningful dosage assessment must begin by identifying the ingredient form, converting milligrams into micromoles, accounting for myrosinase-dependent conversion, and reviewing evidence for the exact finished formulation.
For supplement brands, the optimal dose is not the maximum dose. It is the dose that achieves:
- Verifiable sulforaphane delivery
- Acceptable consumer tolerability
- Stability throughout shelf life
- Clear and accurate labeling
- Claims supported by appropriate evidence
KSNutripharma helps supplement brands develop direct sulforaphane and glucoraphanin-plus-myrosinase formulations with customized serving sizes, delayed-release capsules, potency testing and shelf-life validation.
Explore our Sulforaphane Supplement OEM Services
Contact our formulation team to evaluate the appropriate delivery system for your target market.
